Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial-Reference-Cited by-同舟云学术

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Published:2019-09 Issue:9 Volume:20 Page:1226-1238
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Saura Cristina,Hlauschek Dominik,Oliveira Mafalda,Zardavas Dimitrios,Jallitsch-Halper Anita,de la Peña Lorena,Nuciforo Paolo,Ballestrero Alberto,Dubsky Peter,Lombard Janine M,Vuylsteke Peter,Castaneda Carlos A,Colleoni Marco,Santos Borges Giuliano,Ciruelos Eva,Fornier Monica,Boer Katalin,Bardia Aditya,Wilson Timothy R,Stout Thomas J,Hsu Jerry Y,Shi Yi,Piccart Martine,Gnant Michael,Baselga José,de Azambuja Evandro

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer;Miller;Breast Cancer Res,2011

2. AACR Project GENIE: powering precision medicine through an international consortium;Cancer Discov,2017

3. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer;Baselga;J Clin Oncol,2009

4. Everolimus in postmenopausal hormone receptor positive ER positive breast cancer;Baselga;N Engl J Med,2012

5. Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from BOLERO-2;Hortobagyi;J Clin Oncol,2016

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Phosphatidylinositol 3-kinase Inhibitors for Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials;Current Cancer Drug Targets;2024-09

2. Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions;Molecular Cancer;2024-08-10

3. Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond;Critical Reviews in Oncology/Hematology;2024-08

4. Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression;Molecular Oncology;2024-06-12

5. Reporting on patient’s body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review;Breast Cancer Research;2024-05-22